The news has had no effect on the market. Maybe already factored in only valuing OCTP at around 3.5 million. Shame as valued at 10 million+ last year without a product at phase 1. Think it’s the same across most Pharma at the moment.
I wonder if they will be announced shortly after Easter. Although the USA is a Private Health setting I am sure like the NHS consultants and senior medical staff will be off during the holidays and there would be no point in breaking any analysis due to staff availability. Just a thought.
Hopefully there will be as sudden reversal that benefits us long term holders who have remained hopeful on the clinical outcome while experiencing increasing dilution and its the shorters who get punished for a change.
You can buy up to 6million shares on Halifax before it goes to Negotiated settlement. I don’t know what the maximum sell is as I don’t have enough shares to achieve it . Can’t recall such large availability of shares to be able to buy since Mint.
Mr India They generally say companies get brought out when they have a product but there is not the confidence in management. Hemo share price to the potential of the product seems to show low market confidence. Maybe why shorting around this share has always been so active. Any rise on Scientific news is followed by a funding fall. Just how it seems.
Mr India I feel we are much more diluted than we should be. The company managed to raise at 7 around covid. Then there was the Mint disaster. No lessons were learned. Here we are. Great advance in Science but at a greater rate of dilution than I had hoped. I have always said the Science and the Money management should be separate. I know it’s Vlads company but surely when you list you are answerable to share holders.